Prudential Financial Inc Nurix Therapeutics, Inc. Transaction History

Prudential Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.94 - $29.65 $536,945 - $1.23 Million	-41,495 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $337,643 - $440,737	12,775 Added 44.48%	41,495 $1.23 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $454 - $733	20 Added 0.07%	28,720 $861,000
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $18,157 - $26,917	750 Added 2.68%	28,700 $762,000
Q1 2021 May 12, 2021	BUY	$26.98 - $50.17 $754,091 - $1.4 Million	27,950 New	27,950 $869,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.